Phase I – Bioequivalence

295 trials 18 recruiting

Filter these 295 trials by condition, country, sponsor and more.

Open in Search →

Evaluating Bioequivalence of a Fixed Dose Combination versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin. Ended

2024-519852-10-00 No medical condition. 2025-09-10
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm… Ended

2025-522976-10-00 Not applicable (submitted trial is a BE study in health 2025-09-10
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg… Ended

2025-522562-70-00 infection 2025-09-08
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin. Ended

2024-519850-35-00 No medical condition 2025-09-04
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin Ended

2024-510791-20-00 Healthy volunteers 2025-08-29
The bioavailability study of Dapagliflozin Ended

2025-522234-31-00 not applicable (submitted trial is a bioequivalence stu 2025-08-20
Randomised, crossover bioequivalence clinical trial of escitalopram 10 mg capsules versus escitalopram 10 mg film-coated tablets, after a si… Ended

2025-522124-26-00 Antidepressants 2025-08-18
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid f… Ended

2025-521718-24-00 infections 2025-07-28
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolit… Ended

2024-519801-36-00 Myelofibrosis, polycythemia vera, acute and chronic gra 2025-07-14
Bioequivalence of Canagliflozin 300 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended

2024-519109-36-00 No medical condition. 2025-07-09
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants. Ended

2025-520737-23-00 No medical condition. 2025-07-07
Bioequivalence clinical trial of two formulations of loperamide. Ended

2025-521549-26-00 Healthy volunteers 2025-07-02
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-… Ended

2025-521722-15-00 infections 2025-06-26
Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg tablets versus edoxaban 60 mg film-coated tablets, after a single oral… Ended

2025-522225-35-00 Healthy volunteers 2025-06-23
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants. Ended

2025-520736-41-00 No medical condition 2025-06-17
Evaluation of the bioequivalence of two products containing esomeprazole under fasting conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. … Ended

2024-512401-89-00 No therapeutic indication in the current trial with hea 2025-06-12
Phase 1 study on SAR443122 bioavailability and food effect in healthy adults Ended

2025-521073-13-00 Colitis ulcerative 2025-06-11
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin Ended

2024-514050-75-01 Healthy volunteers 2025-06-04
Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy P… Ended

2024-519567-18-00 No medical condition. 2025-06-02
Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl Ended

2023-504698-19-00 Bioequivalence trial in healthy volunteers 2025-05-30
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participant… Ended

2024-519470-39-00 No medical condition. 2025-05-30
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participant… Ended

2024-519250-37-00 No medical condition. 2025-05-27
A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation… Ended

2024-514725-38-00 Maintenance bronchodilator treatment to relieve symptom 2025-05-26
An open label, randomized, single-dose, two-treatment, two-period, cross-over pilot bioequivalence study comparing Pyridostigmine Bromide, P… Ended

2025-521177-14-00 treatment of myasthenia gravis 2025-05-15